For example, 2-methoxyestradiol (Panzem) inhibits HIF-1a protein synthesis and transcriptional activity has been used in combination with bevacizumab (VEGF mAb) in a Phase II clinical trial for metastatic carcinoid neuroendocrine tumor, result in reduced the tumor size in 68% of cancer patients (Kulke et al., 2011). The gene discussed is HIF1A; the disease is cancer.